Citryll Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 18

Employees
  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $20.8M

  • Investors
  • 7

Citryll General Information

Description

Developer of pharmaceutical drugs intended to treat autoimmune and other human diseases. The company's drugs include the formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes, enabling doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage due to sepsis.

Contact Information

Website
www.citryll.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Kloosterstraat 9
  • 5349 AB Oss
  • Netherlands

Citryll Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Citryll Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 02-Jul-2020 $20.8M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 03-Jul-2019 0000 0000 Completed Generating Revenue
To view Citryll’s complete valuation and funding history, request access »

Citryll Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of pharmaceutical drugs intended to treat autoimmune and other human diseases. The company's drugs include the
Drug Discovery
Oss, Netherlands
18 As of 2022
000.00
0000000000 0 000.00

000-00

do consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000 000000000
Vienna, VA
00 As of 0000
000.00
000000000 000.00

000000

uis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur
0000 000000000
Indianapolis, IN
0 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Citryll Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CEL-SCI Corporate Backed or Acquired Vienna, VA 00 000.00 000000000 000.00
0000000 0000000000 Venture Capital-Backed Indianapolis, IN 0 000.00 0000000000 0 000.00
0000000 0000000000 Formerly VC-backed Dallas, TX 00 00000 000000&0 00000
000000 00000000000 Venture Capital-Backed Weston, FL 0 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed PA 000 00000 00000000 00000
You’re viewing 5 of 40 competitors. Get the full list »

Citryll Patents

Citryll Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4085973-A1 Inhibition of eosinophil extracellular traps Pending 04-May-2021 000000000 0
GB-202012326-D0 Diagnostic Inactive 07-Aug-2020 00000000000
AU-2019326740-A1 Antibodies binding to citrullinated histone 2a and/or 4 Pending 21-Aug-2018 000000000
EP-3841120-A1 Antibodies binding to citrullinated histone 2a and/or 4 Pending 21-Aug-2018 000000000
US-11345750-B2 Antibodies binding to citrullinated histone 2a and/or 4 Active 21-Aug-2018 C07K16/18 0
To view Citryll’s complete patent history, request access »

Citryll Executive Team (5)

Name Title Board Seat Contact Info
Renato Chirivi Ph.D Co-Founder & Chief Technology Officer
Patrick Round Chief Medical Officer
Helmuth Van Es Ph.D Co-Founder, Chief Executive Officer & Board Member
Marlon Dijkshoorn Chief Financial Officer
Eric Meldrum Ph.D Chairman & Chief Scientific Officer
To view Citryll’s complete executive team members history, request access »

Citryll Board Members (8)

Name Representing Role Since
Daniela Couto Ph.D Self Board Member 000 0000
Eric Meldrum Ph.D Self Chairman & Chief Scientific Officer 000 0000
Helmuth Van Es Ph.D Self Co-Founder, Chief Executive Officer & Board Member 000 0000
Mariette van der Velden-Roesink Self Board Observer 000 0000
Nora Frey Ph.D Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Citryll Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Citryll Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioGeneration Ventures Venture Capital Minority 000 0000 000000 0
Laurel Venture Capital Venture Capital Minority 000 0000 000000 0
Seventure Partners Venture Capital Minority 000 0000 000000 0
Brabantse Ontwikkelings Maatschappij Growth/Expansion Minority 000 0000 000000 0
BrightGene Bio-Medical Technology Company Corporation Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »